NEW YORK (360Dx) – Amydis Diagnostics said that the National Institute on Aging had awarded it a Phase 2 SBIR grant of $1.8 million to fund R&D into an ophthalmic diagnostic probe for Alzheimer's disease.

The ability to identify amyloid-beta deposits helps in identifying patients at risk for Alzheimer's disease and enables enrollment of patients in clinical trials investigating disease modifying treatments, and may ultimately guide therapeutic intervention at an early stage, the firm said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.